Literature DB >> 25623248

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients.

Nicola De Stefano1, Douglas L Arnold2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25623248     DOI： 10.1177/1352458514564494

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  17 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 3.  Autonomic function and brain volume.

Authors:  Juan M Racosta; Kurt Kimpinski
Journal:  Clin Auton Res       Date:  2016-08-27       Impact factor: 4.435

Review 4.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

Review 5.  MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.

Authors:  M P Wattjes; M D Steenwijk; M Stangel
Journal:  Clin Neuroradiol       Date:  2015-07-23       Impact factor: 3.649

6.  Image Quality Evaluation in Clinical Research: A Case Study on Brain and Cardiac MRI Images in Multi-Center Clinical Trials.

Authors:  Michael Osadebey; Marius Pedersen; Douglas Arnold; Katrina Wendel-Mitoraj
Journal:  IEEE J Transl Eng Health Med       Date:  2018-08-23       Impact factor: 3.316

7.  The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.

Authors:  Sheena L Dupuy; Shahamat Tauhid; Shelley Hurwitz; Renxin Chu; Fawad Yousuf; Rohit Bakshi
Journal:  Neurol Ther       Date:  2016-10-15

8.  Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).

Authors:  Stephane Nave; Rachelle S Doody; Mercè Boada; Timo Grimmer; Juha-Matti Savola; Paul Delmar; Meike Pauly-Evers; Tania Nikolcheva; Christian Czech; Edilio Borroni; Benedicte Ricci; Juergen Dukart; Marie Mannino; Tracie Carey; Emma Moran; Inma Gilaberte; Nicoletta Milani Muelhardt; Irene Gerlach; Luca Santarelli; Susanne Ostrowitzki; Paulo Fontoura
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.

Authors:  Nicola De Stefano; Diego G Silva; Michael H Barnett
Journal:  CNS Drugs       Date:  2017-04       Impact factor: 5.749

Review 10.  Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).

Authors:  Stanley L Cohan; Barry A Hendin; Anthony T Reder; Kyle Smoot; Robin Avila; Jason P Mendoza; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2021-07-06       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.